EcoDrugPlus

Bcl2 Like 1

Ensembl ID : ENSSARG00000012171
Gene Symbol: BCL2L1
1 External references
286 Possible Orthologues:

Bcl2 Like 2

Ensembl ID : ENSSARG00000002771
Gene Symbol: BCL2L2
1 External references
64 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSSARG00000014162
Gene Symbol: BTK
1 External references
207 Possible Orthologues:

C-C Motif Chemokine Receptor 1

Ensembl ID : ENSSARG00000009428
Gene Symbol: CCR1
1 External references
299 Possible Orthologues:

C-X-C Chemokine Receptor Type 2-Like

Ensembl ID : ENSSARG00000009820
Gene Symbol: LOC101555581
2 External references
237 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSSARG00000007060
Gene Symbol: CXCL8
3 External references
183 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSSARG00000012121
Gene Symbol: CFTR
1 External references
216 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSSARG00000006730
Gene Symbol: DNMT1
1 External references
206 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSSARG00000005235
Gene Symbol: TOP1
1 External references
270 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSSARG00000012331
Gene Symbol: TOP2A
1 External references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSSARG00000003185
Gene Symbol: TOP2B
1 External references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSSARG00000014446
Gene Symbol: EML4
1 External references
212 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).